The arena of therapeutics for Niemann-Pick Disease Type C (NPC) is a rapidly changing one, with significant strides being made in investigation. Several promising therapeutic approaches are currently progressing pre-clinical evaluation, offering encouragement for individuals living with this infrequent and deteriorating brain-related disorder. A m